Please login to the form below

Not currently logged in
Email:
Password:

pancreatic adenocarcinoma.

This page shows the latest pancreatic adenocarcinoma. news and features for those working in and with pharma, biotech and healthcare.

EU green light for Novartis' skin cancer therapy

EU green light for Novartis' skin cancer therapy

Other studies of the drug are ongoing in prostate cancer, pancreatic adenocarcinoma, ovarian cancer, non-small cell lung cancer and triple-negative breast cancer, as well as haematological malignancies such as

Latest news

  • BMS and Celgene to research cancer immunotherapy combo BMS and Celgene to research cancer immunotherapy combo

    Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer. ... pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.

  • BMS and Celgene to research cancer immunotherapy combo BMS and Celgene to research cancer immunotherapy combo

    Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer. ... pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.

  • Merck KGaA starts third phase III trial for cancer hope TH-302 Merck KGaA starts third phase III trial for cancer hope TH-302

    Merck KGaA has started a phase III trial of its novel cancer candidate TH-302 in patients with locally advanced or metastatic pancreatic adenocarcinoma. ... The new phase III trial -called MAESTRO - aims to enrol 600 patients and will compare TH-302 plus

  • Amgen-Takeda's ganitumab fails in pancreatic cancer study

    Amgen-Takeda's ganitumab fails in pancreatic cancer study. Interim analysis shows no improvement in overall survival. ... The phase III trial - codenamed GAMMA - was looking at the effects on survival of adding ganitumab to gemcitabine in the first-line

  • RNA interference rebirth RNA interference rebirth

    pancreatic adenocarcinoma. I. ALN-VSP. Alnylam. VEGF/KSP. liver cancers. I. ALN-TTR. Alnylam.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    Take the pancreatic adenocarcinoma scenario for example, if the drug developers had targeted their research in Europe instead of the USA, one could have found a much more favourable research environment. ... 7) EpiomicTM Patient Segmentation Database,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics